The Global Health and Economic Burden of Hospitalizations for Heart FailureAndrew P. Ambrosy, Mihai Gheorghiade, Gregg C. Fonarow et al.|Journal of the American College of Cardiology|2014Cited by 2k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Scott D. Solomon|The Lancet|2022Cited by 881
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, Morten Schou et al.|New England Journal of Medicine|2024Cited by 693
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trialsMuthiah Vaduganathan, Scott D. Solomon, Brian Claggett et al.|The Lancet|2020Cited by 645